4:48 PM
 | 
Dec 27, 2012
 |  BC Extra  |  Top Story

OMS103HP misses Phase III endpoint

Omeros Corp. (NASDAQ:OMER) said OMS103HP missed the primary endpoint of improving knee symptoms from baseline to day 30 vs. vehicle irrigation solution in a Phase III trial of the product to improve post-operative...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >